Choose the best clinical strategy with the help of our seasoned clinical drug development experts.…
Early access
ICTA set up a department dedicated to the conduct of Early Access and Compassionate Use programmes 18 years ago, managed by qualified staff who use dedicated processes and tools.
Today, ICTA is leader in conducting these programmes with a long history of successful programmes.
18 YEARS OF EXPERIENCE IN THE MANAGEMENT OF
EARLY ACCESS AND COMPASSIONATE USE PROGRAMMES
In July 2021, a new French legislation came into force. Its aim was to simplify existing mechanisms, making early access and off-label use easier for all users, and to ensure the sustainability of these programmes for the public health insurance system. It streamlined the access pathways into two distinct routes:
EARLY ACCESS
Pre- or Post-marketing authorisation
The Early Access Authorisation allows the use of an innovative medicinal product for which the manufacturer agrees to apply for a marketing authorisation or, if already authorised, to submit for inclusion in the reimbursement lists (post-MA). These two options are:
- The pre-marketing Early Access Authorisation (AP1)
- and the post-marketing Early Access Authorisation (AP2)
Drugs are eligible for the authorisation of an Early Access provided they meet the five following criteria:
- The patient is affected by a serious, rare, or disabling disease
- There is no therapeutic alternative
- The treatment cannot be delayed
- The treatment is presumed to be innovative
- There is a strong presumption that the product is effective and safe based on the results of therapeutic trials.
COMPASSIONATE access
Compassionate prescription schemes
There are two types of Compassionate Access schemes:
- The Compassionate Use Authorisation (French acronym: AAC), granted for a named patient, renewable, and open to medicines which do not have a MA in any indication
- and the Compassionate Prescription Scheme (French acronym: CPC), granted for a period of three years, renewable, and open to medicines which have a MA in another indication.
They allow the use of a medicinal product which is not necessarily innovative or initially intended to obtain a marketing authorisation, but which meets a therapeutic need.
To be eligible, drugs must fulfil the following criteria:
- There is no clinical research underway for commercial purposes
- There is no appropriate treatment
- Drug efficacy and safety are presumed based on the available clinical data.
ICTA builds on 18 years of experience in the management of Early Access and Compassionate Use programmes across a broad range of therapeutic areas to offer:
AN INTEGRATED SUITE OF SERVICES
for the management of your early access and compassionate use programmes including:
Consulting regarding the implementation of the new regulation
Support in the preparation of the EAP/CUP dossier: writing of PUT-RD/PUT-SP, regulatory aspects
Dedicated unit with hotline for healthcare professionals
Management of compensation agreements with the sites
Development of an EAP platform with Pasrel/ATIH connection and project-specific functionalities/workflows
One-stop portal giving access to all EAP/CUP platforms deployed by ICTA for the same laboratory or product
Online data monitoring
Validation of treament access requests in EAPs
Pharmacovigilance management
Processing of data according to ICTA standard procedures
Management of treatment orders
A solId expertise valued by our clients
- Integrated operational approach (specific processes, specialised skills, dedicated resources)
- Centralised management
- Quality focused data collection process with close monitoring of sites and immediate communication to collect missing data
- In-house data processing on a continuous basis, writing of periodic reports
- Assistance to healthcare professionnals
- IT platform for data collection compliant with new requirements (Pasrel/ATIH and multi-factor authentication)
- Secure data flows to guarantee data integrity
- Experience across a wide range of therapeutic areas
- Ability to bring methodological and technical insight in your projects requiring matching with SNDS data
OTHER AREAS OF EXPERTISE
Early access
ICTA set up a department dedicated to the conduct of Early Access and Compassionate Use…
Real World Evidence
With a large experience in health data assessments, ICTA teams are able to define the…
Health data analysis
Today we have access to increasingly large data sources. Advanced technologies surch as Artificial Intelligence…
Medical device
Experienced in the regulatory requirements for clinical investigations of medical and in-vitro diagnostic devices, we…
Decentralised studies
Our three-fold expertise in the regulatory, digital, and logistics fields makes ICTA a partner of…
